However, in an experimental diabetic retinopathy cell model, melatonin delays diabetic retinopathy (DR) progression by upregulating MEG3 and inhibiting model cell activation and pro-inflammatory cytokine production via the MEG3/miR-204/SIRT1 axis (Tu et al., 2021). Here, SIRT1 is linked to diabetic retinopathy.